Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic eligibility

C J Ellis1, J K French, H D White

  • 1Department of Medicine, Auckland Hospital, New Zealand.

Australian and New Zealand Journal of Medicine
|October 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dental Societies and Dental Literature: Read before the Eighth District Dental Society of the State of New York.

The Independent practitioner·2023
Same author

Common genetic variants do not predict recurrent events in coronary heart disease patients.

BMC cardiovascular disorders·2022
Same author

Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome.

Journal of internal medicine·2021
Same author

OakEcol: A database of Oak-associated biodiversity within the UK.

Data in brief·2019
Same author

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.

Journal of internal medicine·2017
Same author

UK service level audit of insulin pump therapy in paediatrics.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same journal

Gastroenterological Society of Australia, Annual Scientific Meeting, May 1980.

Australian and New Zealand journal of medicine·2020
Same journal

'A touch of sugar'--a dangerous euphemism still alive and well.

Australian and New Zealand journal of medicine·2001
Same journal

Silent myocardial ischaemia following methysergide overdose.

Australian and New Zealand journal of medicine·2001
Same journal

Extensive jugular and upper limb thrombosis in a patient with factor V Leiden mutation and non-Hodgkin's lymphoma.

Australian and New Zealand journal of medicine·2001
Same journal

Visual loss as the presenting feature of giant cell arteritis.

Australian and New Zealand journal of medicine·2001
Same journal

Lymphoproliferative disease causing angioedema--an uncommon association.

Australian and New Zealand journal of medicine·2001
See all related articles

Thrombolytic therapy benefits patients with ischemic chest pain and ST elevation or bundle branch block on ECG. This treatment is recommended for specific patient subsets, including those with inferior myocardial infarction and delayed presentation.

Area of Science:

  • Cardiology
  • Emergency Medicine
  • Pharmacology

Background:

  • Ischemic chest pain requires prompt diagnosis and treatment.
  • Electrocardiogram (ECG) findings guide the decision for thrombolytic therapy.
  • The Fibrinolytic Therapy Trialists' Collaborative Group established benefits for specific patient groups.

Purpose of the Study:

  • To evaluate thrombolytic eligibility in various patient subsets presenting with ischemic chest pain.
  • To explore benefits in patients with inferior myocardial infarction.
  • To confirm treatment benefits for patients presenting 6-12 hours after symptom onset.

Main Methods:

  • Analysis of data from the Fibrinolytic Therapy Trialists' Collaborative Group.
  • Review of ECG criteria for thrombolytic therapy eligibility.

Related Experiment Videos

  • Examination of treatment outcomes in specific patient subgroups.

    • Main Results:

    • Patients with ischemic chest pain, ST elevation or bundle branch block on ECG benefit from thrombolytic therapy.
    • Therapy is beneficial for patients with inferior myocardial infarction.
    • Patients presenting 6-12 hours after symptom onset also show treatment benefits.

    Conclusions:

    • Thrombolytic therapy should be considered for eligible patients regardless of specific conditions.
    • Diabetic patients, elderly patients, menstruating women, and those who have undergone cardiopulmonary resuscitation should not be routinely excluded.
    • ECG interpretation remains crucial for guiding thrombolytic treatment decisions.